RecruitingPhase 2NCT06496607
A Study to Evaluate Solriktug in Adult Participants With Asthma
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Adult Participants With Asthma (RAINIER)
Sponsor
Uniquity One (UNI)
Enrollment
140 participants
Start Date
Jul 26, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria6
- Participant must be aged 18 to 75 years of age.
- Documented diagnosis of asthma at least 12 months prior to Screening.
- Participants must be on maintenance asthma medications, for at least 3 months prior to screening: inhaled corticosteroid (ICS) in combination with long-acting beta agonist (LABA), or as part of an approved triple therapy for asthma (ICS/LABA/long-acting muscarinic antagonist \[LAMA\]).
- Participant has an ACQ-6 score ≥1.5 at Screening Visit.
- Participant has FEV1 of ≥50% to 90%, inclusive, of predicted normal value at Screening Visit 1.
- Evidence of asthma as documented by reversibility in FEV1 of ≥12% and ≥200 mL over the pre-salbutamol FEV1 at Screening Visit.
Exclusion Criteria7
- Female participant who is pregnant or breastfeeding.
- Participant is a current smoker, or former smoker with a smoking history of ≥10 pack-years.
- Participant has a known hypersensitivity to any component of the formulation of solrikitug, including any of the excipients, or a history of anaphylactic reaction to any therapeutic monoclonal antibody.
- Participant has history or evidence of any clinically significant cardiovascular, hematologic, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy, or any other condition (risks factors of pneumonia) that in the opinion of the Investigator might obfuscate the study data.
- Participant has an exacerbation of asthma requiring use of OCS or hospitalization in the 6 weeks prior to Screening or during the Screening Period.
- Participant has history or evidence of any clinically significant pulmonary condition, other than asthma.
- Lower respiratory tract infection within the 6 weeks prior to Screening.
Interventions
BIOLOGICALNSI-8226
Solrikitug
BIOLOGICALNSI-8226
Solrikitug
BIOLOGICALNSI-8226
Solrikitug
BIOLOGICALPlacebo
Placebo
Locations(74)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06496607
Related Trials
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267393 locations
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619138 locations
Relationship of Airway Microbiota, Endotype and Phenotype in Adult Asthma
NCT047069881 location
To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong Kong
NCT046397911 location
Genetic Association With Various Severities, Phenotypes and Endotypes of Asthma.
NCT061960342 locations